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Summary 
Despite progression in anticancer drug development and improvements in the clinical 
utilisation of therapies, current treatment regimes are still dependent upon the use of 
systemic antiproliferative cytotoxic agents. Although these agents are unquestionably 
potent, their efficacy is limited by toxicity toward ‘normal’ cells and a lack of tumour 
selective targeting, resulting in a therapeutic index which is modest at best. 
Consequently, the development of more tumour selective cancer treatments, with 
better discrimination between tumour and normal cells is unequivocally an important 
goal for cancer drug discovery. One such strategy is to exploit the tumour phenotype 
as a mechanism for tumour-selective delivery of potent therapeutics. An exciting 
approach in this area is to develop anticancer therapeutics as prodrugs, which are non-
toxic until activated by enzymes localised specifically in the tumour. Enzymes 
suitable for tumour-activated prodrug development must have increased activity in the 
tumour relative to non-diseased tissue and an ability to activate the prodrug to its 
active form. One class of enzyme satisfying these criteria are the tumour 
endoproteases, particularly the serine- and metallo- proteases. These proteolytic 
enzymes are essential for tumour angiogenesis, invasion and metastasis, the major 
defining features of malignancy. This review describes the concept behind 
development of tumour-endoprotease activated prodrugs and discusses the various 
studies to date that have demonstrated the huge potential of this approach for 
improvement of cancer therapy.  
 
Keywords: Cancer therapy, Endoprotease, Prodrug, Drug delivery, Matrix 
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Abbreviations: 
ECM, extracellular matrix; EGFR, epidermal growth factor receptor; FITC, 
fluorescein isothiocyanate; L-Dox, leucine-doxorubicin; MMP, matrix 
metalloproteinase; MTD, maximum tolerated dose; MT-MMP, membrane-tethered 
matrix metalloproteinase; NQO1, NAD(P)H: quinone oxidoreductase type 1; PSA, 
prostate specific antigen; TAP, tumour activated prodrug; TNFα, tumour necrosis 
factor alpha. 
Introduction 
Despite vast improvements in detection, diagnosis and treatment over the past decade, 
cancer still remains one of the most frequent causes of death worldwide(Varmus, 
2006). Therefore, new more effective treatment strategies are required to impact upon 
this issue. To date, surgical resection remains the number one priority for treatment of 
solid tumours. Despite this, for the majority of solid tumours cure by surgical 
resection is not feasible, either as a consequence of tumour accessibility, tumour 
pathology or the presence of tumour spread and metastasis. Therefore, 
chemotherapeutic interventions are required and essential both as a treatment in their 
own right and as an adjuvant to localised treatment such as surgery and radiotherapy. 
Whilst many advances have been made in the area of anticancer drug development 
(reviewed in Collins et al., 2006; Newell, 2005), “classical” antiproliferative cytotoxic 
agents still form the basis of many current treatment regimens (Collins et al., 2006). 
Despite being potent with the ability to kill large numbers of tumour cells, the clinical 
efficacy of these “classical” agents is limited by their unavoidable toxicity to ‘normal’ 
cells and their lack of tumour selective targeting. With such compounds, the 
therapeutic index for tumour versus normal tissue is modest, toxic side effects are the 
norm and the development of resistance often occurs. As such, most currently utilised 
anticancer agents have a very small therapeutic index based on the high frequency of 
systemic toxicities and the need for large concentrations of active drug at the tumour 
site (Verweij et al., 2000). Consequently, a plateau of effectiveness has been reached 
with these agents. 
 An increased understanding of the molecular basis of cancer has led to many 
advancements in cancer chemotherapy which has now entered an era of “targeted 
molecular therapeutics”- agents exploiting defined abnormalities responsible for the 
causation, maintenance, expansion or metastatic potential of cancer (reviewed in 
(Collins et al., 2006; Newell, 2005). The development of new therapeutics with 
increased tumour selectivity, better discrimination between tumour and normal tissue, 
lower systemic toxicity and thus a larger therapeutic index, is possibly the most 
important aim of current cancer drug discovery. One such strategy is the development 
of agents to perturb the dysregulated molecular pathways involved in cancer 
development and progression, e.g. Gleevec (imatinib) and Zolinza (vorinostat), 
resulting in therapies directed at the precise molecular pathology driving progression 
of specific tumour types (reviewed in (Collins et al., 2006; Newell, 2005).  Despite 
these successes, the identification of such critical targets for drug development is 
complicated due to both the characteristic genetic instability of cancer and the diverse 
nature of genetic changes involved in the tumorigenic process (Collins et al., 2006; 
Huang et al., 2001).  
 An alternative strategy for more effective and targeted cancer therapeutics is 
the development of agents which take advantage of the tumour phenotype rather than 
intracellular signalling pathways, i.e. differential cell-matrix interactions, altered cell 
surface receptor expression and increased capacity for proteolytic degradation (Huang 
et al., 2001). In this respect, epidermal growth factor receptor (EGFR) has been 
demonstrated as a clinically viable drug target as evidenced by the success of the 
small molecule drugs Iressa (gefitinib) and Tarceva (erlotinib) (Collins et al., 2006). 
  A further strategy to increase drug targeting and decrease systemic toxicities 
is to deliver potent chemotherapeutics selectively to their intended site i.e. the tumour 
microenvironment. One such approach is the development of therapeutic agents as 
non-toxic prodrugs, termed tumour-activated prodrugs (TAPs), in a form whereby the 
potent therapeutic entity is masked until being activated by exploitation of unique 
phenotypic differences present in the tumour environment, (depicted in Figure 1) 
(Denny, 2001). 
Classically, the term prodrug encompasses all compounds that are activated 
after administration either enzymatically, chemically or spontaneously to form a 
pharmacologically active species. In this sense the concept of prodrugs within cancer 
chemotherapy is not new as demonstrated by cyclophosphamide, a clinically utilised 
prodrug of a nitrogen mustard alkylating agent activated in the liver by the 
cytochrome P450 enzyme system (Boddy et al., 2000; Connors, 1986; Torkelson et 
al., 1974). In the context of cyclophosphamide and the majority of cancer 
chemotherapeutics classified as prodrugs to date, these agents are not designed as 
TAPs, but rather as derivatives to modify drug uptake or pharmacokinetics. Unlike the 
TAP strategy, the use of prodrugs such as these is still limited by normal tissue 
toxicities due to their potential activation outside of the tumour environment 
(Rooseboom et al., 2004). As such, this family of prodrugs can be regarded as those 
in which the pharmacological properties of the active drug are modified to facilitate 
increased tumour delivery rather than those which are directed specifically at the 
tumour (Bruno et al., 2007; Ganesh, 2007; Rooseboom et al., 2004). 
With the rapid expansion in our understanding of the molecular pathology of 
cancer and improved knowledge of “classical” and more recently “targeted” cancer 
therapies, we now have a robust framework by which to progress the development 
and assessment of therapeutics directed to the tumour for selective conversion to 
active therapeutic agents, specifically tumour activated prodrugs (TAPs).   
 
Tumour Activated Prodrugs (TAPs). 
As mentioned above, Tumour activated prodrugs (TAPs) are systemic compounds 
that are activated selectively in tumour tissue by exploiting a unique physiological, 
metabolic or genetic difference between tumour and normal cells (Denny, 2001). 
TAPs must undergo selective cellular metabolism in tumours to generate their potent 
therapeutic agent. In general, TAPs are comprised of a minimum of three domains: 
trigger, linker and effector, where the “trigger” (controlling selectivity) is joined to the 
“effector” (responsible for therapeutic effect) by a “linker”; the prodrug remaining 
non-toxic until activation of the trigger (shown in figure 1) (Denny, 2001).  
 The primary step in the development of TAPs is the identification of enzymes 
capable of metabolising these agents selectively within tumour tissue. There is 
considerable evidence demonstrating differential expression of a panoply of enzymes 
between normal and tumour tissue, although consistent patterns of enzyme 
upregulation so far remain elusive (Denny, 2001). The ideal characteristics for tumour 
enzymes suitable for targeting by TAPs are; 
i) Good characterisation of the enzyme or family of enzymes possessing a 
known role in tumour development and/or progression 
ii) Demonstration of a high affinity of the enzyme for the prodrug 
iii) Significantly elevated expression in the disease state and activity in the 
tumour environment 
iv) Low or negative expression and lack of enzymatic activity in non-diseased 
tissue 
v) No presence of the enzyme in a prodrug-activating form in patient serum 
vi) Capability by the enzyme for selective and rapid activation of the prodrug 
 
In the context of TAPs, several phenotypic characteristics of the tumour have 
been suggested as selective prodrug targets involving a range of endogenous enzyme 
classes including oxidoreductases, transferases, hydrolases, and lyases (reviewed in 
(Rooseboom et al., 2004). An example of one area which has attracted considerable 
attention as a target for TAP therapeutics is tumour hypoxia, induced as a 
consequence of the poorly defined vascular network of many solid tumours. 
Bioreductively activated prodrugs e.g. Tirapazamine and banoxantrone (AQ4N) 
(McKeown et al., 2007; Patterson et al., 2000), specifically target hypoxic cells by 
becoming selectively activated under low oxygen tension by enzymes including 
NQ01 and cytochrome P450 reductase (McKeown et al., 2007). This class of TAP is 
showing great promise in cancer clinical trials (McKeown et al., 2007). Targeting 
enzymes centrally involved in the main defining features of cancer is an attractive 
strategy for TAP development since these will provide optimal targets for TAPs by 
virtue of the phenotypic differences between “normal” and tumour cells. One class of 
enzyme which satisfy all criteria for TAP development and have been heavily 
implicated in tumour development and progression are the proteolytic endoproteases, 
the main focus of this review. 
 
Central involvement of endoproteases in cancer development 
The major defining features of malignant tumours are their ability to acquire an 
improved vasculature system, penetrate into surrounding normal tissues and 
disseminate to distant sites. Each one of these processes relies heavily upon the 
increased expression and activity of diverse extracellular endoproteases from multiple 
enzymatic classes, namely the metalloproteases and the serine, threonine, cysteine and 
aspartic proteases. These proteases constitute the cancer degradome- the repertoire of 
proteases that cells and tissues co-ordinately regulate in order to modulate their local 
environment (Lopez-Otin et al., 2002; Overall et al., 2007). These endoproteases are 
frequently upregulated within tumour tissue where they promote the development and 
expansion of the tumour, formation of new blood vessels to support the burgeoning 
energy demands of the rapidly growing tumour, and facilitate the metastasis of cancer 
cells to distant organs (Egeblad et al., 2002). 
 It has long been recognised that cellular invasion of basement membranes and 
connective tissue stroma and angiogeneisis and metastasis, involve the actions of 
diverse extracellular proteases, particularly the matrix metalloproteinase (MMP) and 
serine protease families. The initial belief that these proteases function solely to 
mediate tissue destruction and clear an invasive path allowing cell migration and thus 
tumour expansion is now known to be oversimplistic, with these enzymes having 
major roles in growth factor activation, cellular adhesion, cellular survival and 
immune surveillance to name but a few (Egeblad et al., 2002; Hojilla et al., 2003; 
McCawley et al., 2001). There is now a considerable body of literature demonstrating 
elevated expression of many of these endoproteases in primary tumours and 
metastases, with the majority demonstrating an association to tumour progression or 
validity as prognostic indicators of clinical outcome (Brinckerhoff et al., 2000; Kamat 
et al., 2006; Vizoso et al., 2007). Taken together their broad but essential role in 
tumorigenesis and their relationship to disease prognosis, these enzymes can be 
defined as a significant force in the phenotypic evolution of cancer. 
 
Tumour Endoproteases as targets for tumour selective anticancer drug delivery 
The involvement of endoproteases in tumour development, expansion and metastasis 
is unequivocal, as outlined above and reviewed extensively elsewhere (Borgono et al., 
2004; Egeblad et al., 2002; Lee et al., 2004; Mohamed et al., 2006; Overall et al., 
2007; Overall et al., 2006b). In terms of drug development, proteases provide a 
significant opportunity as they account for approximately 2% of mammalian genes 
and represent 5% of all drug targets (Lee et al., 2004; Overall et al., 2007; Overall et 
al., 2006a). Within the protease family the serine and metalloproteases constitute the 
largest group (accounting for 65% of all proteases) with central roles in neoplastic and 
malignant processes (Borgono et al., 2004; Deryugina et al., 2006; Lopez-Otin et al., 
2002; Mohamed et al., 2006; Overall et al., 2007). The main driving principles behind 
utilisation of an enzyme for TAP development is increased activity in the tumour 
environment relative to non-diseased tissue, and an ability to selectively cleave the 
prodrug to its active form (Denny, 2001). In this respect, the serine and 
metalloproteases are ideal candidates for TAP development due to both their elevated 
activity in the extracellular tumour environment and their ability to selectively and 
specifically cleave short peptide sequences. Consequently, the increased endoprotease 
activity within tumours relative to non-diseased tissue can be harnessed to activate 
peptide-conjugated prodrugs of potent anticancer therapeutics, resulting in high levels 
of the active agent at the tumour and low or negative drug levels in ‘normal’ tissues. 
The concentration of active therapeutic selectively released and deposited in the 
tumour is highly dependent upon both the catalytic efficiency of the targeted 
endoprotease and the level to which the enzyme is expressed within the tumour. As 
such, when developing such strategies, careful consideration must be given to target 
efficiency and suitability for TAP activation, as well as the potency and mechanism of 
action for the active therapeutic agent. In recent years several endoprotease targeted 
TAPs have been reported in the literature, initially against the serine protease Prostate 
Specific Antigen (PSA), and latterly the matrix metalloprotease (MMPs) family, as 
discussed below. 
  
Serine Proteases: Prostate Specific Antigen (PSA) as a target for Prodrugs:  The 
serine protease Prostate Specific Antigen (PSA), is a secreted member of the 
kallikrein gene family, which as the name implies is expressed selectively in prostatic 
tissue (Borgono et al., 2004). In cancers of the prostate, PSA levels are significantly 
elevated relative to non-diseased tissue (Denmeade et al., 2001; Wong et al., 2001). In 
addition, PSA is a clinically utilised serological diagnostic marker of prostate cancer, 
with higher levels being indicative of a larger tumour burden or metastatic disease 
(Rao et al., 2007; Reynolds et al., 2007). In terms of PSA as a target for TAP 
development via the criteria outlined above; PSA is elevated and proteolytically 
active at high levels in prostatic tumours whilst all normal tissues lack detectable PSA 
activity, and it is capable of selective and rapid activation of peptide-conjugated 
prodrugs (DeFeo-Jones et al., 2000; Denmeade et al., 1998; Reynolds et al., 2007; 
Wong et al., 2001). Furthermore, PSA present in patient serum is proteolytically 
inactive and incapable of prodrug activation due to formation of a complex with the 
plasma protease inhibitors α1-antichymotrypisn and α2-microglobulin, thereby 
fulfilling another major criteria for TAP development (Otto et al., 1998; Reynolds et 
al., 2007). Taken together, these characteristics of PSA strongly supported its 
potential for TAP development, as discussed below. 
 
Matrix Metalloproteinases (MMPs) as targets for Tumour Activated Prodrugs:  The 
Matrix Metalloproteinases (MMPs), a family of at least 24 zinc dependent 
endoproteases, possess the ability to degrade most, if not all components of the 
extracellular matrix (ECM) and basement membrane, contributing to the formation of 
a microenvironment permissive of tumour growth, angiogenesis and metastasis 
(Deryugina et al., 2006; Egeblad et al., 2002). A number of MMPs have been 
associated with tumour cell invasion evidenced by a significant correlation between 
the extent of local tissue penetration and MMP levels (Deryugina et al., 2006; 
McCawley et al., 2000; McCawley et al., 2001).  
 In addition to the classical role of MMPs in the degradation of the ECM, 
MMPs are also able to cleave a wide range of non-matrix substrates including those 
involved in apoptosis, cell dissociation, cell-cell communication and cell division, 
thereby negating the initial view that MMPs functioned purely to “bulldoze” the ECM 
and facilitate cell invasion (Deryugina et al., 2006; Egeblad et al., 2002; Hojilla et al., 
2003; McCawley et al., 2001). Extensive studies have demonstrated frequent 
overexpression of several MMPs in many forms of human tumour (Atkinson et al., 
2007b; Brinckerhoff et al., 2000; Hoekstra et al., 2001; Kamat et al., 2006; Vizoso et 
al., 2007) with a clear relationship between increased MMP expression and poor 
clinical outcome in a number of cancers including; breast (MMP-11), colon (MMP-1), 
gastric (MMP-2 and MMP-9), non-small cell lung cancer (MMP-13), oesophageal 
(MMP-7), small cell lung cancer (MMP-3, MMP-11 and MMP-14) (Hoekstra et al., 
2001; Vizoso et al., 2007). Furthermore, expression of specific MMPs has been 
shown in many independent studies to serve as both prognostic indicators of clinical 
outcome and markers of tumour progression in a diverse range of tumour types 
(Brinckerhoff et al., 2000; Kamat et al., 2006; Vihinen et al., 2002; Vizoso et al., 
2007; Zucker et al., 2004). 
 The MMPs may be divided into eight distinct groups: five are secreted and 
three are membrane bound (MT-MMPs) (Egeblad et al., 2002). The majority of 
MMPs, with the exception of the MT-MMPs and MMP-11, -21, -23 and -28, are 
secreted by the cell as inactive zymogens and require activation extracellularly by 
cleavage of the N-terminal pro-domain resulting in a fully functional enzyme 
(Brinckerhoff et al., 2002). In contrast, the MT-MMP family are not secreted from the 
cell but are activated intracellularly and presented on the cell surface in a 
proteolytically active state (Brinckerhoff et al., 2002; Osenkowski et al., 2004). 
Therefore, all MMPs possess proteolytic activity in the extracellular 
microenvironment within the tumour, distinct from the lack of activity present in 
‘normal’ tissues. 
 Many eloquent experiments have been performed in recent years which 
undeniably demonstrate a crucial role for MMPs in tumorigenesis through a number 
of potential mechanisms, detailed extensively in the literature (Deryugina et al., 2006; 
Egeblad et al., 2002; Hojilla et al., 2003; McCawley et al., 2000; McCawley et al., 
2001). For example, overexpression of MMP-14 (MT1-MMP) in cell lines null for 
MMP-14 or non-malignant epithelial cells afforded the cells the capability to invade 
(Soulie et al., 2005). Conversely, in many models in which MMP-14 is knocked 
down, a reduction in cellular invasiveness and tumour progression is observed 
(Deryugina et al., 2006; Rutkauskaite et al., 2005; Sabeh et al., 2004; Ueda et al., 
2003; Zhang et al., 2006). Therefore, the MMPs are a family of extracellular 
proteases which demonstrate the potential to become efficient drug targets for TAP 
development, facilitating release of therapeutic agents selectively in the tumour 
microenvironment. 
 An interesting point when considering the value of MMPs for TAP 
development is the actual sub-tumoral expression of the specific protease. In many 
cases, MMPs within the tumour are not-specifically produced by the tumour cells 
themselves, but rather by the host stromal cells within or adjacent to the invading 
tumour (Egeblad et al., 2002; Jodele et al., 2006). Although initially thought to be 
problematic for TAP development, in reality this may actually prove to be beneficial 
for this strategy for two reasons. Firstly, the important issue for TAP success is the 
elevation of active MMP selectively within the tumour microenvironment, leading to 
local release of the active therapeutic and toxicity toward tumour cells. Since MMP 
activity is known to be restricted to the tumour mass, the expression of MMPs by 
stromal cells only increases the level of target for tumour-selective TAP activation. 
Secondly, stromal cells producing MMPs are known to facilitate malignant behaviour 
(Egeblad et al., 2002; Jodele et al., 2006), therefore toxicity against these cells may in 
itself prove beneficial. As such, the expression of MMPs by many cell types within 
the tumour microenvironment is perceived a positive factor for development and 
success of tumour-selective MMP-activated TAPs. 
 
Tumour activated prodrugs directed to the serine protease, Prostate Specific 
Antigen (PSA) 
There are now numerous examples in the literature regarding the targeting of PSA 
with a variety of TAPs. Drug conjugates including doxorubicin (DeFeo-Jones et al., 
2002; Denmeade et al., 1998; DiPaola et al., 2002; Wong et al., 2001), vinblastine 
(DeFeo-Jones et al., 2002), 5-fluorodeoxyuridine (Mhaka et al., 2002), thapsigargin 
(Denmeade et al., 2003) and paclitaxel (Kumar et al., 2007) have been investigated 
and resulted in promising preclinical data. The creation of a proteolytic cleavage map 
of PSA against its physiological substrate semenogelin I, led to the identification of a 
heptapeptide sequence rapidly hydrolysed by PSA (DeFeo-Jones et al., 2000). 
Covalent linkage of this peptide sequence to the aminoglycoside portion of 
doxorubicin (a topoisomerase II poison) led to the creation of L-377202, a TAP 
hydrolysed by PSA resulting in the release of leucine-doxorubicin and subsequently 
doxorubicin (DeFeo-Jones et al., 2000). When evaluated in preclinical studies, a 
substantial therapeutic index was demonstrated for L-377202 and molar equivalent 
doses of the prodrug eight to nine-fold higher than doxorubicin alone could be 
administered in vivo without additional toxicity (DeFeo-Jones et al., 2000; DiPaola et 
al., 2002). In clinical trials, only a 1.3-fold molar increase in prodrug relative to 
doxorubicin alone was administered due to dose limiting neutropenia, although at this 
dose a substantial reduction was noted in mean PSA percentage, an indicator of 
tumour volume (DiPaola et al., 2002). Further clinical trials are yet to be reported for 
this agent. 
 Following demonstration of proof of concept with L-377202, several other 
PSA directed chemotherapeutic TAPs have been now reported with relative success 
(DeFeo-Jones et al., 2002; Denmeade et al., 2003; Kumar et al., 2007; Mhaka et al., 
2002). Using the chemical strategy outlined for L-377202, DeFeo-Jones and 
coworkers subsequently developed a PSA-directed TAP incorporating the 
microtubule-targeted agent vinblastine (depicted in figure 2), with the aim of 
increasing efficacy over L-377202 against advanced prostate cancer (DeFeo-Jones et 
al., 2002). In preclinical studies, this TAP demonstrated PSA-dependent activation, 
significantly lower toxicity in both mice and dogs compared to desacetyl-vinblastine 
(effector) alone, and a significant inhibition in the growth of PSA-producing tumours 
in vivo (DeFeo-Jones et al., 2002). In addition, the vinblastine-conjugate was shown 
to have a superior therapeutic index compared to the doxorubicin-conjugate, L-
377202 (DeFeo-Jones et al., 2002). Clinical evaluation of this agent has yet to be 
reported. In another study, PSA-targeted TAPs have been developed incorporating the 
potent SERCA pump inhibitor thapsigargin, the cytotoxicity of which is regardless of 
proliferative state and thus effective against characteristically slow growing prostate 
tumours (Denmeade et al., 2003). In agreement with previous approaches, 
thapsigargin-TAPs were selectively effective against PSA-producing prostate cells 
both in vitro and in vivo (Denmeade et al., 2003). Continuous administration of this 
TAP in vivo resulted in complete growth inhibition of PSA-producing prostate cancer 
xenografts but not PSA-negative renal carcinomas xenografts (Denmeade et al., 
2003). This thapsigargin TAP is reportedly being evaluated in clinical trials for 
metastatic prostate cancer (Denmeade et al., 2003). The development of PSA-
activated prodrugs has also been described for both paclitaxel and 5-
fluorodeoxyuridine, although only in vitro results have been reported to date (Kumar 
et al., 2007; Mhaka et al., 2002). 
 The success of PSA-targeted chemotherapeutics has recently resulted in the 
expansion of the TAP concept into the biological arena, incorporating a bacterial 
cytolytic protein (aerolysin) rather than a chemotherapeutic effector (Williams et al., 
2007). This PSA-activated protoxin (PRX302) when administered intratumorally in 
vivo caused minimal effect against PSA-null tumours, but complete remission of 
PSA-secreting tumour models. In addition, no toxicity was observed in organs 
adjacent to the prostate following intratumoral injection, supporting the specificity of 
this agent towards PSA. Clinical trials are currently underway to assess PRX302 as an 
intraprostatic treatment for recurrent prostate cancer (Williams et al., 2007). 
 
Tumour activated prodrugs directed to the Matrix Metalloproteinases (MMPs) 
To date, a small number of MMP-targeted prodrugs have been developed, most 
commonly towards the secreted family members MMP-2 and MMP-9 (Albright et al., 
2005; Atkinson et al., 2007a; Kline et al., 2004; Kratz et al., 2001; Mansour et al., 
2003; Mincher et al., 2002; Timar et al., 1998; Van Valckenborgh et al., 2005; Young 
et al., 2003). One of the first studies to assess MMP-2 mediated tumour selective 
prodrug activation involved the incorporation of the alkylating agent melphalan into 
an MMP-2-cleaveable hexapeptide (termed MHP), a derivation of the TAP conjugate 
depicted in figure 1 (Timar et al., 1998). Although in vitro cytotoxicity of MHP 
proved disappointing, the melphalan effector was successfully liberated in the 
presence of MMP-2/-9 and conditioned media from MMP-positive tumour cells, 
thereby supporting the potential for MMP targeted TAPs (Timar et al., 1998). 
Subsequent strategies to develop MMP-targeted TAPs were based upon the structure 
outlined in figure 1, in which the effector therapeutic was conjugated to the terminus 
of the peptide sequence rather than being incorporated within it (as for MHP). One 
such TAP was a water-soluble maleimide derivative of doxorubicin, incorporating a 
peptide sequence suggested to be selectively cleaved by MMP-2 (Kratz et al., 2001; 
Mansour et al., 2003). In addition to having doxorubicin attached at one end of the 
conjugate, this TAP was also developed to bind to serum albumin, with the aim of 
using albumin as a macromolecular carrier to increase tumour accumulation of the 
TAP (Kratz et al., 2001; Mansour et al., 2003). Efficient activation of this TAP to 
release doxorubicin was demonstrated using both purified MMP-2 and MMP-2 
positive tissue homogenates.  In vivo, the maximum tolerated dose (MTD) for 
albumin-bound doxorubicin was substantially higher than for doxorubicin alone and 
subsequent studies showed superior activity against A375 melanoma at equitoxic 
doses (Mansour et al., 2003). The concept of macromolecular delivery of MMP-
activated TAPs has also been investigated by several other groups with differing 
success (Chau et al., 2006a; Chau et al., 2006b; Chau et al., 2004; Tauro et al., 2005).  
 In contrast to the use of macromolecules as delivery vehicles, MMP-activated 
TAPs conforming to the simple ‘trigger-linker-effector’ structure, shown in figure 1, 
have shown significant potential as anticancer therapeutics. In one approach an 
anthraquinone topoisomerase inhibitor (NU:UB31) was linked to the C-terminus of an 
MMP-9 cleavable heptapeptide, and the N-terminus of the peptide was ‘capped’ with 
fluorescein isothiocyanate (FITC), to produce a TAP, EV1-FITC (Mincher et al., 
2002; Van Valckenborgh et al., 2005; Young et al., 2003). The FITC in this prodrug 
allows for prodrug cleavage to be observed fluorescently, since the FITC is quenched 
by the anthraquinone in the intact TAP, a factor which is not present following TAP 
activation. Using a murine myeloma model, TAP metabolism in tissues ex vivo was 
higher in MMP-9 expressing tumour-bearing organs (bone marrow, spleen) relative to 
other tissues (heart, lung, kidney), as determined by fluorescence from FITC release 
(Van Valckenborgh et al., 2005). There was however a significant level of prodrug 
activation in non-diseased tissue homogenates, suggesting a lack of TAP specificity 
towards MMP-9 (Van Valckenborgh et al., 2005). An attempt to further increase 
MMP-selectivity was addressed using peptidomimetic analogues of TAPs, 
incorporating doxorubicin, auristatins and the duocarmycins (Kline et al., 2004). 
However, these peptidomimetic TAPs were either not activated by the MMPs or 
demonstrated no selective activity against MMP-positive versus MMP-negative cells. 
These studies suggest careful consideration of the effector molecule and the peptide 
sequence is paramount for the success of these TAPs. 
In the most detailed study reported to date, MMP-targeted TAPs of 
doxorubicin were demonstrated to show a much higher therapeutic index than 
doxorubicin alone, using the MMP expressing HT1080 preclinical model (Albright et 
al., 2005). In this strategy the peptide length was shown to be central to both 
compound stability and MMP-cleavage efficiency, with a heptapeptide containing 
three or four amino acids to the carboxy side of the scissile bond being optimal 
(depicted in Figure 3) (Albright et al., 2005). Similar to EV1-FITC, these prodrugs 
were capped on the free peptide end to prevent unrequired exopeptidase degradation 
(Figure 3). The optimised TAPs were activated by the secreted MMPs, MMP-2 and 
MMP-9, and the membrane-tethered MMP, MMP-14 (MT1-MMP), but not the 
endoprotease neprilysin, reinforcing their selectivity towards the MMP family. In an 
advancement of previous approaches, these TAPs were shown to be 
pharmacologically stable in vivo and preferentially metabolised in MMP-expressing 
tumours relative to heart and plasma, resulting in a 10-fold increase in the 
tumour/heart ratio relative to administration of doxorubicin alone (Albright et al., 
2005). In addition, the optimised TAP resulted in an 80% cure rate against the 
HT1080 xenograft model, compared to only 10% with doxorubicin alone. One 
potential downside of this approach was that a significant fraction of leucine-
doxorubicin (L-Dox) formed in the tumour, as a consequence of TAP-activation, was 
not rapidly metabolised to release doxorubicin (figure 3), allowing for diffusion of L-
Dox away from the tumour to other tissues before conversion to doxorubicin, with 
potential consequences for induction of normal tissue toxicity (Albright et al., 2005). 
Further evaluation of these TAPS and their progression towards clinical trials has yet 
to be reported. 
In addition to exploiting MMPs to activate cytotoxic agents linked to peptides, 
preliminary work has been undertaken to develop MMP-activated biotoxins, 
incorporating anthrax toxin, measles toxin, cytolysin, CD95-L and tumour-necrosis 
factor alpha (TNF-α) (Gerspach et al., 2006; Liu et al., 2000; Potrich et al., 2005; 
Springfeld et al., 2006; Watermann et al., 2007).  The strategy for these agents is 
similar to that for MMP-activated cytotoxins in that the therapeutic moiety is bound to 
a MMP-cleavable sequence which acts to inactivate the agent until released 
selectively in the tumour.  Although the potential for all these strategies was 
successfully demonstrated in vitro, antitumour data is only reported for the measles 
virus biotoxin, which demonstrated potent MMP-dependent activity (Springfeld et al., 
2006) 
Whilst a number of studies, outlined above, have endeavoured to harness the 
proteolytic power of the MMPs to selectively metabolise and thus activate TAPs, 
these attempts have in many cases not proved as fruitful as anticipated. The most 
likely explanation for this is the primary focus of strategies towards peptide 
conjugation of the ‘effector’ and the subsequent inactivation of this agent as a TAP 
rather than upon the design of the ‘trigger’ or peptide sequence. Determination of the 
optimal peptide sequence to facilitate both pharmacological stability in vivo and 
selective cleavage by the MMPs (or even specific MMP family members) is now 
known to be the most crucial and difficult step in design of TAPs against 
endoproteases, specifically the MMPs. 
 
Tumour Endoprotease Activated agents: The Future? 
As discussed herein, development of agents targeted towards the tumour by exploiting 
their increased endoprotease activity is an area of drug development showing great 
potential and promise. Several strategies and approaches have been evaluated with 
mixed results, all of which have led to a significant increase in our knowledge and 
understanding of this area. It is important to remember that in addition to these 
prodrugs improving tumour-selective delivery of cancer therapeutics, they function in 
parallel to reduce the unrequired activity of these agents against normal tissues, 
including liver, heart and bone marrow. In this sense these TAPs could be developed 
to deliver agents to the tumour which in practise could not be delivered due to 
extensive normal tissue toxicities and a consequent narrow therapeutic index.  
The determination of new endoprotease targets, protease substrates and overall 
substrate sequence requirements for individual proteases will be essential in the future 
development of TAPs.  It is only once these enzyme requirements are fully 
understood that truly proficient and selective TAPs may be designed.  Since proteases 
account for 2% of the human genome and regulate virtually every biological process, 
determining protease substrate specificities will be essential if TAPs are to be 
designed to be selectively activated by one only enzyme family, or indeed, one 
enzyme.  Overlapping substrate specificities between protease families must be 
understood and addressed in the future design of these agents. In addition, 
improvements in our knowledge and understanding of other endoprotease systems 
overactive in cancer will further improve and increase the potential of this approach. 
In support of this, urokinase plasminogen activator (uPA), a serine endoprotease, was 
suggested as a valid target for TAP development (Romer et al., 2004), against which 
tumour-selective protoxins have been recently developed (Rono et al., 2006). 
In summary, studies to date have demonstrated the worth of endoprotease 
targeted TAPs. Based on these encouraging studies, drug development strategies need 
to be accelerated to realise the clinical potential of these prodrugs.  
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Figure Legends: 
 
Figure 1 Schematic representation of tumour endoprotease activated prodrugs 
(TAPs).  The prodrug is composed of three domains: a potent therapeutic agent 
(effector), an endoprotease cleavable peptide sequence (trigger), and a linker to join 
the trigger to the effector. This TAP remains inactive until activation of the trigger. 
The presence of the endoprotease in the tumour but not ‘normal’ tissues results in 
activation of the TAP trigger selectively in the tumour, causing the release of the 
potent effector and a subsequent therapeutic effect. 
Figure 2 A) Structure of tumour-activated prodrug incorporating the 
microtubule-targeted agent vinblastine targeted at the serine protease, prostate specific 
antigen (PSA) (DeFeo-Jones et al., 2002). Vinblastine is attached at the 4-position to 
an octapeptide incorporating a PSA-selective cleavage site. The prodrug is endcapped 
by acetylation to prevent non-specific exopeptidase activation.  B) Schematic 
representation of prodrug activation by PSA. The cleavage site for PSA within the 
peptide is indicated by the arrow. Following the initial cleavage by PSA the remaining 
amino acid residues are removed rapidly by exopeptidases. 
Figure 3 A) Structure of MMP-targeted tumour-activated prodrug incorporating 
the cytotoxic agent doxorubicin (Albright et al., 2005). Doxorubicin is attached to a 
heptapeptide incorporating a MMP-selective cleavage site. The prodrug is endcapped 
by acetylation to prevent non-specific exopeptidase activation and promote in vivo 
drug stability.  B) Schematic representation of prodrug activation by MMP with 
expected cleavage products. The cleavage site for MMP within the peptide is 
indicated by the arrow. Following the initial cleavage by MMP the remaining amino 
acid residues are removed rapidly by exopeptidases. 
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